Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
ACE Inhibitors Trial — Nursing Care Plan
Purpose: Provide safe, evidence-based nursing care for patients enrolled in a clinical trial of ACE (angiotensin-converting enzyme) inhibitors. Focus areas: baseline assessment, monitoring for therapeutic effect and adverse reactions (especially hypotension, hyperkalemia, renal impairment, and angioedema), patient education, documentation, and communication with the research team.
Nursing Diagnoses (possible)
Risk for decreased cardiac output related to antihypertensive effect of ACE inhibitor.
Risk for injury related to orthostatic hypotension.
Risk for electrolyte imbalance (hyperkalemia) related to ACE inhibitor therapy.
Risk for renal impairment related to ACE inhibitor use.
Risk for ineffective health management related to inadequate knowledge about trial protocol, side effects, and medication adherence.
Risk for allergic reaction/anaphylaxis (angioedema) related to ACE inhibitor.
Assessment
Baseline data: obtain complete medication history (prescription, OTC, herbal supplements), past medical history (especially renal disease, heart failure, prior angioedema), allergies, and current vital signs.
Baseline labs: serum creatinine, BUN, electrolytes (potassium), baseline CBC as per protocol, urinalysis for proteinuria if indicated.
Cardiac and volume status: heart rate, blood pressure (supine, sitting, standing to assess orthostatic changes), lung sounds (for crackles/edema), peripheral edema.
Respiratory assessment: observe for cough (dry, persistent cough is common side effect) and respiratory distress (wheeze, stridor).
Skin and mucosal assessment: swelling of lips, tongue, face, or throat suggestive of angioedema.
Neurologic status: level of consciousness, dizziness, syncope episodes.
Adherence and comprehension: patient understanding of trial schedule, dosing, follow-up, and restrictions (e.g., potassium supplements, NSAIDs).
Pregnancy status for patients of childbearing potential: pregnancy test per protocol — ACE inhibitors are teratogenic.
Nursing Interventions
Monitor vital signs: check blood pressure and heart rate per protocol; obtain orthostatic vitals before and after initial dosing and during dose changes.
Monitor intake and output and daily weights if indicated for fluid status.
Laboratory monitoring: obtain serum creatinine and potassium prior to initiation, within 1–2 weeks after initiation or dose changes, and at intervals required by the trial. Notify research clinician for creatinine increase >30% from baseline or potassium >5.0 mEq/L (or per protocol thresholds).
Observe for signs of angioedema: sudden facial/lip/tongue swelling, hoarseness, stridor, respiratory distress. If angioedema suspected: stop ACE inhibitor, call rapid response/medical provider immediately, prepare airway management, administer emergency meds per ACLS/anaphylaxis protocols as ordered.
Manage hypotension: if symptomatic (dizziness, syncope, oliguria), place patient supine with legs elevated, ensure airway and breathing, assess blood pressure and heart rate, hold dose per protocol, notify provider. Consider IV fluids cautiously if hypovolemia suspected and ordered.
Review concomitant medications: identify drugs that increase risk of hyperkalemia (potassium-sparing diuretics, potassium supplements, NSAIDs), nephrotoxins (NSAIDs, certain antibiotics), or potentiate hypotension (other antihypertensives). Communicate recommended adjustments to research team.
Provide cough management: assess severity and impact on quality of life; document and report persistent dry cough—may require medication change per protocol.
Pregnancy prevention counseling: reinforce strict avoidance of pregnancy, discuss contraception per protocol and refer for obstetric consultation if pregnancy occurs.
Education and adherence support: teach patient about purpose of ACE inhibitor in the trial, expected benefits, common side effects (dizziness, cough), serious adverse effects (angioedema, hyperkalemia, renal dysfunction), signs to report immediately, timing of labs and clinic visits, dietary guidance (avoid excess potassium/salt substitutes unless instructed), and avoiding NSAIDs without approval.
Emergency preparedness: instruct patient to seek immediate care for breathing difficulty or facial swelling; provide contact numbers for trial team and after-hours emergencies.
Documentation: record baseline assessments, lab values, vital signs, adverse events, patient education, consent confirmation (if applicable), medication administration times/doses, and communication with the research team following trial and institutional policies.
Collaboration: communicate promptly with the principal investigator, study coordinator, and pharmacy about adverse events, lab abnormalities, or nonadherence. Participate in protocol-specified reporting of serious adverse events.
Evaluation
Therapeutic response: improved blood pressure control as measured against baseline and trial endpoints without unacceptable adverse effects.
Safety outcomes:
ACE Inhibitors Trial — Nursing Care Plan
Purpose: Provide safe, evidence-based nursing care for patients enrolled in a clinical trial of ACE (angiotensin-converting enzyme) inhibitors. Focus areas: baseline assessment, monitoring for therapeutic effect and adverse reactions (especially hypotension, hyperkalemia, renal impairment, and angioedema), patient education, documentation, and communication with the research team.
Nursing Diagnoses (possible)
Risk for decreased cardiac output related to antihypertensive effect of ACE inhibitor.
Risk for injury related to orthostatic hypotension.
Risk for electrolyte imbalance (hyperkalemia) related to ACE inhibitor therapy.
Risk for renal impairment related to ACE inhibitor use.
Risk for ineffective health management related to inadequate knowledge about trial protocol, side effects, and medication adherence.
Risk for allergic reaction/anaphylaxis (angioedema) related to ACE inhibitor.
Assessment
Baseline data: obtain complete medication history (prescription, OTC, herbal supplements), past medical history (especially renal disease, heart failure, prior angioedema), allergies, and current vital signs.
Baseline labs: serum creatinine, BUN, electrolytes (potassium), baseline CBC as per protocol, urinalysis for proteinuria if indicated.
Cardiac and volume status: heart rate, blood pressure (supine, sitting, standing to assess orthostatic changes), lung sounds (for crackles/edema), peripheral edema.
Respiratory assessment: observe for cough (dry, persistent cough is common side effect) and respiratory distress (wheeze, stridor).
Skin and mucosal assessment: swelling of lips, tongue, face, or throat suggestive of angioedema.
Neurologic status: level of consciousness, dizziness, syncope episodes.
Adherence and comprehension: patient understanding of trial schedule, dosing, follow-up, and restrictions (e.g., potassium supplements, NSAIDs).
Pregnancy status for patients of childbearing potential: pregnancy test per protocol — ACE inhibitors are teratogenic.
Nursing Interventions
Monitor vital signs: check blood pressure and heart rate per protocol; obtain orthostatic vitals before and after initial dosing and during dose changes.
Monitor intake and output and daily weights if indicated for fluid status.
Laboratory monitoring: obtain serum creatinine and potassium prior to initiation, within 1–2 weeks after initiation or dose changes, and at intervals required by the trial. Notify research clinician for creatinine increase >30% from baseline or potassium >5.0 mEq/L (or per protocol thresholds).
Observe for signs of angioedema: sudden facial/lip/tongue swelling, hoarseness, stridor, respiratory distress. If angioedema suspected: stop ACE inhibitor, call rapid response/medical provider immediately, prepare airway management, administer emergency meds per ACLS/anaphylaxis protocols as ordered.
Manage hypotension: if symptomatic (dizziness, syncope, oliguria), place patient supine with legs elevated, ensure airway and breathing, assess blood pressure and heart rate, hold dose per protocol, notify provider. Consider IV fluids cautiously if hypovolemia suspected and ordered.
Review concomitant medications: identify drugs that increase risk of hyperkalemia (potassium-sparing diuretics, potassium supplements, NSAIDs), nephrotoxins (NSAIDs, certain antibiotics), or potentiate hypotension (other antihypertensives). Communicate recommended adjustments to research team.
Provide cough management: assess severity and impact on quality of life; document and report persistent dry cough—may require medication change per protocol.
Pregnancy prevention counseling: reinforce strict avoidance of pregnancy, discuss contraception per protocol and refer for obstetric consultation if pregnancy occurs.
Education and adherence support: teach patient about purpose of ACE inhibitor in the trial, expected benefits, common side effects (dizziness, cough), serious adverse effects (angioedema, hyperkalemia, renal dysfunction), signs to report immediately, timing of labs and clinic visits, dietary guidance (avoid excess potassium/salt substitutes unless instructed), and avoiding NSAIDs without approval.
Emergency preparedness: instruct patient to seek immediate care for breathing difficulty or facial swelling; provide contact numbers for trial team and after-hours emergencies.
Documentation: record baseline assessments, lab values, vital signs, adverse events, patient education, consent confirmation (if applicable), medication administration times/doses, and communication with the research team following trial and institutional policies.
Collaboration: communicate promptly with the principal investigator, study coordinator, and pharmacy about adverse events, lab abnormalities, or nonadherence. Participate in protocol-specified reporting of serious adverse events.
Evaluation
Therapeutic response: improved blood pressure control as measured against baseline and trial endpoints without unacceptable adverse effects.
Safety outcomes:
